Allogene Therapeutics, Inc. (ALLO) Return on equity 2019–2025
Allogene Therapeutics, Inc. (ALLO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-65.3%FY2025 · since FY2019: -29.3% → -65.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -65.3% | -4.2 pp |
| FY2024 | -61.0% | +2.9 pp |
| FY2023 | -63.9% | -12.8 pp |
| FY2022 | -51.0% | -31.4 pp |
| FY2021 | -19.7% | +11.5 pp |
| FY2020 | -31.2% | -1.9 pp |
| FY2019 | -29.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice